Markets

XORTX Therapeutics Starts Production Of Drug, Tablet Manufacturing For Its XRx-026 Trial To Treat Gout

Sep 10, 2026 · 04:08 PM ET· updated 1h ago

XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease,

Why It Matters

XORTX started making pills for their gout medicine test in real batches. This shows the company is moving forward with their plan, so watch if they finish testing on time.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

XRTX2.44

+0.29 (+13.21%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.